Ambrosioni E
Department of Clinical Medicine and Applied Biotechnology, Policlinico S. Orsola, Bologna, Italy.
Blood Press Suppl. 1996;5:5-6.
The treatment of hypertensive patients with calcium antagonists favourably influences cardiovascular risk factors as well as the progression of cardiovascular disease. In ongoing large-scale intervention trials, several calcium antagonists are also under investigation for their potential ability to reduce cardiovascular morbidity and mortality in hypertensive patients. The calcium antagonists as a group are heterogeneous, and the haemodynamic effects may vary in accordance with several factors, e.g. vascular selectivity, pharmacokinetic properties, dose schedule and formulation and route of administration. Compared with the older agents, some of the newer dihydropyridines, such as manidipine, have a less negative inotropic effect and less potential for consistent neurohumoral activation.
使用钙拮抗剂治疗高血压患者对心血管危险因素以及心血管疾病的进展具有积极影响。在正在进行的大规模干预试验中，几种钙拮抗剂也在研究其降低高血压患者心血管发病率和死亡率的潜在能力。钙拮抗剂作为一个类别具有异质性，其血流动力学效应可能因多种因素而异，例如血管选择性、药代动力学特性、剂量方案、制剂以及给药途径。与较老的药物相比，一些较新的二氢吡啶类药物，如马尼地平，具有较小的负性肌力作用和较少的持续神经体液激活可能性。
